Depemokimab compared with mepolizumab for relapsing or refractory EGPA on standard of care therapy

The purpose of this study is to learn more about eosinophilic granulomatosis with polyangiitis (EGPA) that returns (relapse) or has not responded to treatment, and if the investigational drug depemokimab can improve the disease. This study is being done to help determine if depemokimab is safe and how it works compared to mepolizumab. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) to treat EGPA. Depemokimab is being compared to mepolizumab, which is approved by the FDA to treat EGPA.

YES. You will be randomly assigned into 1 of 2 groups. One group receives depemokimab and mepolizumab placebo. The other group receives mepolizumab and depemokimab placebo. Placebo means a substance that looks like depemokimab or mepolizumab and is injected in the same way, but it does not have any active drug in it. The study drug and placebo is injected under your skin. This is a double-blind study, which means that you and the study team will not know which group you are in.

We will use your personal health information, information from the tests and procedures done for the study, and information about how the study drug affects you to help determine if depemokimab is safe and effective in treating EGPA.

There are many factors that determine if you are eligible. Some requirements include:

· Adults with EGPA diagnosis and a history of relapsing or refractory disease

· You are on a stable daily dose of 7.5 mg or more of prednisone

· If you are on immunosuppressive therapy, your dose must be stable

You could be in the study for a little over 1 year.

Thank you for your interest! If you wish to learn more and sign up for the study, please contact:

SARAH GILLESPIE
rheumatologyresearch@uphs.upenn.edu
215-614-4417